Integer (NYSE:ITGR) Given “Overweight” Rating at Wells Fargo & Company

Integer (NYSE:ITGR)‘s stock had its “overweight” rating reiterated by investment analysts at Wells Fargo & Company in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. They presently have a $160.00 target price on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 13.90% from the company’s previous close.

Several other brokerages also recently commented on ITGR. KeyCorp raised their target price on Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Truist Financial cut their target price on Integer from $150.00 to $147.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Citigroup raised their target price on Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. Benchmark raised their target price on Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, Bank of America raised their target price on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $142.00.

Integer Trading Down 0.5 %

Shares of ITGR opened at $140.47 on Tuesday. The business has a 50-day moving average of $132.12 and a 200 day moving average of $124.89. Integer has a fifty-two week low of $86.42 and a fifty-two week high of $142.76. The firm has a market cap of $4.71 billion, a P/E ratio of 43.35, a price-to-earnings-growth ratio of 1.99 and a beta of 1.12. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.09 and a current ratio of 3.28.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.07. Integer had a return on equity of 11.63% and a net margin of 6.70%. The company had revenue of $431.42 million during the quarter, compared to analyst estimates of $440.59 million. During the same quarter last year, the firm posted $1.27 EPS. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. As a group, research analysts forecast that Integer will post 5.33 EPS for the current year.

Institutional Trading of Integer

Hedge funds have recently bought and sold shares of the company. Contravisory Investment Management Inc. increased its stake in shares of Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 80 shares during the period. Huntington National Bank increased its stake in shares of Integer by 8,933.3% during the third quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 268 shares during the period. Quest Partners LLC increased its stake in shares of Integer by 3,688.9% during the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 332 shares during the period. GAMMA Investing LLC increased its stake in shares of Integer by 60.9% during the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 142 shares during the period. Finally, Innealta Capital LLC purchased a new position in shares of Integer during the second quarter valued at approximately $110,000. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.